Literature DB >> 16217984

Current and potential uses of imiquimod.

Yuchi C Chang1, Vandana Madkan, Robert Cook-Norris, Karan Sra, Stephen Tyring.   

Abstract

Imiquimod, an imidazoquinoline amine, is an immune response modifier first FDA-approved for the treatment of external genital and perianal warts in 1997. Since its appearance on the market, its antiviral and antitumor properties have been used in the treatment of a variety of dermatologic conditions. In this review article, the basic mechanism of action of imiquimod, current FDA-approved and non-FDA-approved uses of imiquimod, and key points of medication application frequency, possible adverse effects, and use in combination therapy are discussed. Common skin conditions that may be eradicated with imiquimod are emphasized.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16217984     DOI: 10.1097/01.smj.0000176712.01491.98

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  18 in total

1.  Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.

Authors:  Tomoko Hayashi; Michael Chan; John T Norton; Christina C N Wu; Shiyin Yao; Howard B Cottam; Rommel I Tawatao; Maripat Corr; Dennis A Carson; Gregory A Daniels
Journal:  Melanoma Res       Date:  2011-02       Impact factor: 3.599

2.  Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.

Authors:  Tomoko Hayashi; Brian Crain; Maripat Corr; Michael Chan; Howard B Cottam; Roberto Maj; Alcide Barberis; Lorenzo Leoni; Dennis A Carson
Journal:  Int J Urol       Date:  2010-03-11       Impact factor: 3.369

Review 3.  [Urethral condylomata acuminata].

Authors:  W Brummeisl; E Lausenmeyer; F Weber; J Bründl; H-M Fritsche; M Burger; S Denzinger
Journal:  Urologe A       Date:  2015-03       Impact factor: 0.639

4.  Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.

Authors:  E Bart Tarbet; Deanna Larson; Bentley J Anderson; Kevin W Bailey; Min-Hui Wong; Donald F Smee
Journal:  Antiviral Res       Date:  2011-03-23       Impact factor: 5.970

5.  Facile syntheses of functionalized toll-like receptor 7 agonists.

Authors:  Babatope Akinbobuyi; Matthew R Byrd; Charles A Chang; Mysa Nguyen; Zacharie J Seifert; Anne-Laure Flamar; Gerard Zurawski; Katherine C Upchurch; SangKon Oh; Stephen H Dempsey; Thomas J Enke; John Le; Hunter J Winstead; José R Boquín; Robert R Kane
Journal:  Tetrahedron Lett       Date:  2015-01-08       Impact factor: 2.415

6.  Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer.

Authors:  Sang Hoon Rhee; Eunok Im; Charalabos Pothoulakis
Journal:  Gastroenterology       Date:  2008-04-23       Impact factor: 22.682

7.  Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.

Authors:  Floris Fransen; Claire J Boog; Jos P van Putten; Peter van der Ley
Journal:  Infect Immun       Date:  2007-10-01       Impact factor: 3.441

Review 8.  Update on toll-like receptor-directed therapies for human disease.

Authors:  Kevin Tse; Anthony A Horner
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

9.  RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response.

Authors:  Fang Guo; Jennifer Mead; Nishat Aliya; Lijuan Wang; Andrea Cuconati; Lai Wei; Kui Li; Timothy M Block; Ju-Tao Guo; Jinhong Chang
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

10.  Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates.

Authors:  Michael Chan; Tomoko Hayashi; Crystal S Kuy; Christine S Gray; Christina C N Wu; Maripat Corr; Wolfgang Wrasidlo; Howard B Cottam; Dennis A Carson
Journal:  Bioconjug Chem       Date:  2009-06       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.